Clinical Trials Logo
  1. Home
  2. Photorefractive Keratectomy
  3. NCT01381731

A Double-masked, Randomized, Placebo-controlled,Pilot Study of Diquafosol Tetrasodium in Subjects Following Photorefractive Keratectomy (PRK)

Photorefractive Keratectomy Clinical Trial

Clinical Trial Summary

The objectives of this trial are to:

- Assess the safety and tolerability of diquafosol tetrasodium ophthalmic solution versus placebo following one week of treatment in subjects undergoing photorefractive keratectomy (PRK).

- Evaluate the potential of diquafosol to accelerate corneal wound healing/re-epithelialization following PRK.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01381731
Study type Interventional
Source Merck Sharp & Dohme Corp.
Contact
Status Terminated
Phase Phase 2
Start date April 2005
Completion date June 2005
View Details
See also
  Status Clinical Trial Phase
Completed NCT04704518 - Phase IV Study to Evaluate the Efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo After Photorefractive Keratectomy (PRK) Phase 4
Completed NCT04281004 - Processed Amniotic Fluid (PAF) Drops After Photorefractive Keratectomy (PRK) Phase 1/Phase 2
Recruiting NCT05313425 - Effect of Ectoine After Photorefractive Keratectomy (PRK).
Completed NCT00330798 - A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief Phase 4
Recruiting NCT05477875 - Cannabinoid vs Opioid for Photorefractive Keratectomy Pain Control Phase 2
Completed NCT05973253 - Evaluation of Efficacy and Safety of Topical 1% Medroxyprogesterone in the Corneal Epithelium Healing After PRK Phase 2/Phase 3